Buckingham Research Downgrades Salix Pharmaceuticals (SLXP) to Neutral
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Price: $172.81 --0%
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Buckingham Research downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Neutral.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $53.75 yesterday.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $53.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Buckingham ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
